Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 should proceed to Cohort 2, 8mg tablet, without modification. This recommendation was based on the review of the safety data from three patients from Cohort 1 and the absence of any dose limiting toxicitie
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA: